Literature DB >> 26613325

Review of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: an evidence-based approach to diagnosis and management by clinicians.

Alison C Bested, Lynn M Marshall.   

Abstract

This review was written from the viewpoint of the treating clinician to educate health care professionals and the public about Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). It includes: the clinical definition of ME/CFS with emphasis on how to diagnose ME/CFS; the etiology, pathophysiology, management approach, long-term prognosis and economic cost of ME/CFS. After reading this review, you will be better able to diagnose and treat your patients with ME/CFS using the tools and information provided. Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a complex, chronic medical condition characterized by symptom clusters that include: pathological fatigue and malaise that is worse after exertion, cognitive dysfunction, immune dysfunction, unrefreshing sleep, pain, autonomic dysfunction, neuroendocrine and immune symptoms. ME/CFS is common, often severely disabling and costly. The Institute of Medicine (IOM) reviewed the ME/CFS literature and estimates that between 836,000 and 2.5 million Americans have ME/CFS at a cost of between 17 and 24 billion dollars annually in the US. The IOM suggested a new name for ME/CFS and called it Systemic Exertion Intolerance Disease (SEID). SEID's diagnostic criteria are less specific and do not exclude psychiatric disorders in the criteria. The 2010 Canadian Community Health Survey discovered that 29% of patients with ME/CFS had unmet health care needs and 20% had food insecurity--lack of access to sufficient healthy foods. ME/CFS can be severely disabling and cause patients to be bedridden. Yet most patients (80%) struggle to get a diagnosis because doctors have not been taught how to diagnose or treat ME/CFS in medical schools or in their post-graduate educational training. Consequently, the patients with ME/CFS suffer. They are not diagnosed with ME/CFS and are not treated accordingly. Instead of compassionate care from their doctors, they are often ridiculed by the very people from whom they seek help. The precise etiology of ME/CFS remains unknown, but recent advances and research discoveries are beginning to shed light on the enigma of this disease including the following contributors: infectious, genetic, immune, cognitive including sleep, metabolic and biochemical abnormalities. Management of patients with ME/CFS is supportive symptomatic treatment with a patient centered care approach that begins with the symptoms that are most troublesome for the patient. Pacing of activities with strategic rest periods is, in our opinion, the most important coping strategy patients can learn to better manage their illness and stop their post-exertional fatigue and malaise. Pacing allows patients to regain the ability to plan activities and begin to make slow incremental improvements in functionality.

Entities:  

Mesh:

Year:  2015        PMID: 26613325     DOI: 10.1515/reveh-2015-0026

Source DB:  PubMed          Journal:  Rev Environ Health        ISSN: 0048-7554            Impact factor:   3.458


  45 in total

Review 1.  The challenges of chronic pain and fatigue.

Authors:  Jessica A Eccles; Kevin A Davies
Journal:  Clin Med (Lond)       Date:  2021-01       Impact factor: 2.659

2.  Leveraging Prior Knowledge of Endocrine Immune Regulation in the Therapeutically Relevant Phenotyping of Women With Chronic Fatigue Syndrome.

Authors:  Matthew C Morris; Katherine E Cooney; Hooman Sedghamiz; Maria Abreu; Fanny Collado; Elizabeth G Balbin; Travis J A Craddock; Nancy G Klimas; Gordon Broderick; Mary Ann Fletcher
Journal:  Clin Ther       Date:  2019-03-28       Impact factor: 3.393

3.  Unexplained exertional intolerance associated with impaired systemic oxygen extraction.

Authors:  Kathryn H Melamed; Mário Santos; Rudolf K F Oliveira; Mariana Faria Urbina; Donna Felsenstein; Alexander R Opotowsky; Aaron B Waxman; David M Systrom
Journal:  Eur J Appl Physiol       Date:  2019-09-06       Impact factor: 3.078

4.  Rethinking the Standard of Care for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.

Authors:  Fred Friedberg; Madison Sunnquist; Luis Nacul
Journal:  J Gen Intern Med       Date:  2019-10-21       Impact factor: 5.128

Review 5.  Treatment and management of chronic fatigue syndrome/myalgic encephalomyelitis: all roads lead to Rome.

Authors:  Jesus Castro-Marrero; Naia Sáez-Francàs; Dafna Santillo; Jose Alegre
Journal:  Br J Pharmacol       Date:  2017-02-01       Impact factor: 8.739

6.  Effects of Chronic Diurnal Disruption and Acute Inflammatory Challenge on Mice with Latent Murine Gammaherpesvirus Infection.

Authors:  Rita A Trammell; Linda A Toth
Journal:  Comp Med       Date:  2016-12-01       Impact factor: 0.982

7.  Relationship satisfaction, communication self-efficacy, and chronic fatigue syndrome-related fatigue.

Authors:  Sara F Milrad; Daniel L Hall; Devika R Jutagir; Emily G Lattie; Sara J Czaja; Dolores M Perdomo; Gail Ironson; Brian D Doss; Armando Mendez; Mary Ann Fletcher; Nancy Klimas; Michael H Antoni
Journal:  Soc Sci Med       Date:  2019-07-16       Impact factor: 4.634

8.  Exploring Symptom Fluctuations and Triggers in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Using Novel Patient-Centred N-of-1 Observational Designs: A Protocol for a Feasibility and Acceptability Study.

Authors:  Suzanne McDonald; Samuel X Tan; Shamima Banu; Mieke van Driel; James M McGree; Geoffrey Mitchell; Jane Nikles
Journal:  Patient       Date:  2021-08-09       Impact factor: 3.883

9.  Somatic symptoms with psychogenic or psychiatric background: Characteristics and pitfalls.

Authors:  Tetsuya Akaishi; Michiaki Abe; Atsuko Masaura; Junichi Tanaka; Shin Takayama; Ko Onodera; Takehiro Numata; Kota Ishizawa; Satoko Suzuki; Minoru Ohsawa; Takeshi Kanno; Tadashi Ishii
Journal:  J Family Med Prim Care       Date:  2021-02-27

10.  Physical and Mental Fatigue in Subjects Recovered from COVID-19 Infection: A Case-Control Study.

Authors:  Rehab Elanwar; Mona Hussein; Rehab Magdy; Ragaey A Eid; Ahmed Yassien; Ahmed S Abdelsattar; Laila A Alsharaway; Wael Fathy; Amr Hassan; Yasmine S Kamal
Journal:  Neuropsychiatr Dis Treat       Date:  2021-06-22       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.